NASDAQ:CLSN Imunon (CLSN) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free CLSN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.95▼$2.6352-Week Range N/AVolume711 shsAverage Volume150,471 shsMarket Capitalization$13.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Imunon alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Imunon Stock (NASDAQ:CLSN)Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. CLSN Stock News HeadlinesMarch 10, 2024 | morningstar.comImunon Inc IMNNMay 22, 2023 | lse.co.ukCLSN.L Regulatory NewsApril 24, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.October 9, 2022 | marketscreener.comCelsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate - Marketscreener.comOctober 3, 2022 | globenewswire.comImunon Reports Partial Results from Ongoing Non-human Primate Study - GlobeNewswireOctober 3, 2022 | globenewswire.comImunon Appoints James E. Dentzer to its Board of Directors - GlobeNewswireSeptember 29, 2022 | globenewswire.comImunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) - GlobeNewswireSeptember 28, 2022 | globenewswire.comIMUNON to Present at Chardan's 6th Annual Genetic Medicines - GlobeNewswireApril 24, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… September 19, 2022 | globenewswire.comCelsion Corporation Announces Company Name Change to Imunon, Inc. - GlobeNewswireSeptember 19, 2022 | finance.yahoo.comCelsion Corporation Announces Company Name Change to Imunon, Inc.September 15, 2022 | globenewswire.comCelsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer - GlobeNewswireSeptember 15, 2022 | finance.yahoo.comCelsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian CancerSeptember 12, 2022 | benzinga.comCelsion (NASDAQ:CLSN) – Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global I - BenzingaSeptember 12, 2022 | finance.yahoo.comCelsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13September 9, 2022 | benzinga.comCelsion (NASDAQ:CLSN) – Celsion Earnings Perspective: Return On Capital Employed - BenzingaSeptember 9, 2022 | msn.comCelsion Earnings Perspective: Return On Capital EmployedSeptember 7, 2022 | benzinga.comCelsionoration (CLSN) – Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investme - BenzingaSeptember 7, 2022 | globenewswire.comCelsion Corporation to Present at the H.C. Wainwright 24th - GlobeNewswireSeptember 7, 2022 | finance.yahoo.comCelsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 5, 2022 | reuters.comCLSN.OQ - Celsion Corporation | Stock Price & Latest News | ReutersSeptember 1, 2022 | globenewswire.comCelsion Corporation Highlights Progress in its DNA-based Vaccine Program - GlobeNewswireSeptember 1, 2022 | finance.yahoo.comCelsion Corporation Highlights Progress in its DNA-based Vaccine ProgramAugust 30, 2022 | finance.yahoo.comCLSN: Complete Enrollment of OVATION 2 Study Expected in 3Q22…August 15, 2022 | seekingalpha.comCelsion GAAP EPS of -$0.87, revenue of $0.13M - Seeking AlphaAugust 15, 2022 | marketscreener.comCELSION CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q) - Marketscreener.comAugust 15, 2022 | benzinga.comRecap: Celsion Q2 Earnings - BenzingaSee More Headlines Receive CLSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/15/2022Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CLSN CUSIPN/A CIK749647 Webwww.celsion.com Phone(609) 896-9100Fax609-896-2200Employees27Year Founded1982Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,770,000.00 Net Margins-5,229.80% Pretax Margin-5,506.60% Return on Equity-50.18% Return on Assets-36.94% Debt Debt-to-Equity Ratio0.13 Current Ratio6.52 Quick Ratio6.52 Sales & Book Value Annual Sales$500,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.66 per share Price / BookN/AMiscellaneous Outstanding Shares7,099,000Free Float6,768,000Market Cap$13.91 million OptionableOptionable Beta2.27 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael H. Tardugno (Age 71)Exec. Chairman Comp: $1.01MMr. Jeffrey W. Church CPA (Age 65)CPA, CFO, Exec. VP & Corp. Sec. Comp: $528.54kDr. Khursheed Anwer M.B.A. (Age 62)Ph.D., Exec. VP & Chief Scientific Officer Comp: $511.92kDr. Nicholas Borys (Age 63)Exec. VP & Chief Medical Officer Comp: $586.54kDr. Corinne Le Goff M.B.A.Pharm.D., CEO, Pres & DirectorMr. Timothy J. Tumminello (Age 64)Chief Accounting Officer & Controller Ms. Marianne M. LambertsonVP of Communications & Investor RelationsMore ExecutivesKey CompetitorsTraws PharmaNASDAQ:TRAWABVC BioPharmaNASDAQ:ABVCEdesa BiotechNASDAQ:EDSANanoViricidesNYSE:NNVCAvalo TherapeuticsNASDAQ:AVTXView All Competitors CLSN Stock Analysis - Frequently Asked Questions How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:CLSN) released its earnings results on Monday, August, 15th. The biotechnology company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($1.12) by $0.25. Imunon had a negative net margin of 5,229.80% and a negative trailing twelve-month return on equity of 50.18%. During the same period in the previous year, the business earned ($0.90) EPS. When did Imunon's stock split? Imunon shares reverse split on the morning of Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Imunon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Imunon investors own include Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Novan (NOVN), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), Agenus (AGEN) and CBL & Associates Properties (CBL). This page (NASDAQ:CLSN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
